Clinical and virological features of SARS-CoV-2 Omicron variant-infected immunocompromised patients receiving immunosuppressive medications.

Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

COVID-19*/immunology ; COVID-19*/virology ; COVID-19*/epidemiology ; SARS-CoV-2*/immunology ; SARS-CoV-2*/genetics ; Immunocompromised Host* ; Immunosuppressive Agents*/therapeutic use ; Immunosuppressive Agents*/adverse effects; Humans ; Male ; Female ; Middle Aged ; Retrospective Studies ; Adult ; Aged

Background: The prognosis of immunocompromised individuals with COVID-19 remains a significant concern. Information regarding the clinical and virological characteristics of immunocompromised patients infected with SARS-CoV-2 during the Omicron variant period is limited.
Methods: Medical records of patients admitted to our hospital with COVID-19 during the Omicron (BA.1-5) epidemic were retrospectively reviewed. Clinical, virological (nasopharyngeal swabs and blood), and serological data were compared between immunocompromised patients receiving immunosuppressive medications (calcineurin inhibitors, mycophenolate mofetil, or steroids) and control patients not receiving immunosuppressive medications.
Results: Twenty-eight immunocompromised patients (25 transplant recipients) and 26 control patients were included. Fourteen of the immunocompromised patients (50%) received monoclonal antibodies. The immunocompromised group included 15 mild/moderate (53.6%), 10 severe (35.7%), and three critical (10.7%) disease severities. The mortality rate due to COVID-19 during hospitalization was 3.6% (1/28) in the immunocompromised group, with no difference between the two groups. Three cases of re-exacerbation after discharge occurred in the immunocompromised group and none in the control group. Linear regression based on nasopharyngeal real-time-PCR cycle threshold (Ct) values according to the time since symptom onset showed markedly slower viral clearance in the immunocompromised group than in the control group (P slope  = 0.078). In the immunocompromised group, patients who received monoclonal antibodies showed faster viral clearance than those who did not receive monoclonal antibodies. The convalescent anti-spike IgG titers were comparable to those in the control group in patients who received monoclonal antibodies and significantly lower than those in the control patients in patients who did not receive monoclonal antibodies (P < 0.001). The prevalence of viremia at onset was significantly higher in the immunocompromised group than in the control group (35.7%, [10/28] vs. 11.5%, [3/26]; P = 0.003). All three patients with critical disease severity in the immunocompromised group exhibited viremia, one of whom died. All three patients with viremia in the control group were critical, of whom two died.
Conclusions: Immunocompromised individuals receiving immunosuppressive medications are more likely to show delayed post-infection SARS-CoV-2 viral clearance and the development of viremia, potentially resulting in worsening severity and outcomes, especially in viremic patients, even during the Omicron epidemic.
(© 2024. The Author(s).)

Am J Transplant. 2022 Jan;22(1):12-13. (PMID: 34738312)
Clin Infect Dis. 2021 Nov 2;73(9):e2995-e3001. (PMID: 32856036)
N Engl J Med. 2020 Dec 24;383(26):2586-2588. (PMID: 33259154)
J Clin Invest. 2021 Jul 1;131(13):. (PMID: 34196300)
Lancet Infect Dis. 2023 Nov;23(11):1244-1256. (PMID: 37399831)
Transpl Int. 2020 Sep;33(9):1099-1105. (PMID: 32460390)
Cell. 2020 Dec 23;183(7):1901-1912.e9. (PMID: 33248470)
Emerg Infect Dis. 2020 Aug;26(8):. (PMID: 32396505)
Lancet. 2022 Apr 2;399(10332):1303-1312. (PMID: 35305296)
Am J Hematol. 2022 Aug;97(8):E312-E317. (PMID: 35702878)
Am J Transplant. 2022 Jan;22(1):279-288. (PMID: 34514710)
J Infect Dis. 2023 Aug 11;228(3):235-244. (PMID: 36883903)
Lancet Infect Dis. 2023 Jun;23(6):683-695. (PMID: 36796397)
Clin Infect Dis. 2023 Feb 8;76(3):e172-e178. (PMID: 35869843)
Lancet. 2022 Apr 23;399(10335):1618-1624. (PMID: 35397851)
J Antimicrob Chemother. 2022 Sep 30;77(10):2688-2692. (PMID: 35876174)
Lancet Microbe. 2023 Jun;4(6):e431-e441. (PMID: 37116517)
Clin Infect Dis. 2022 Jan 29;74(2):218-226. (PMID: 33949665)
Emerg Infect Dis. 2022 May;28(5):998-1001. (PMID: 35290176)
Am J Pathol. 2022 Apr;192(4):642-652. (PMID: 35123975)
Open Forum Infect Dis. 2023 May 09;10(5):ofad253. (PMID: 37250174)

Keywords: COVID-19; Immunocompromised patients; Immunosuppressive medications; SARS-CoV-2; Severity; Viremia

0 (Immunosuppressive Agents)

SARS-CoV-2 variants

Date Created: 20240726 Date Completed: 20240728 Latest Revision: 20240729

20240729

PMC11282631

10.1186/s12879-024-09633-1

39060971